Company Encyclopedia
View More
name
Ironwood Pharma
IRWD.US
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc.
1.946 T
IRWD.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking118/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-9.92%D
    • Profit Margin8.42%B
    • Gross Margin81.59%A
  • Growth ScoreC
    • Revenue YoY-10.42%D
    • Net Profit YoY1259.11%A
    • Total Assets YoY1.68%C
    • Net Assets YoY15.15%A
  • Cash ScoreC
    • Cash Flow Margin1187.39%B
    • OCF YoY-10.42%D
  • Operating ScoreB
    • Turnover0.86B
  • Debt ScoreE
    • Gearing Ratio166.70%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    The Nasdaq Biotechnology Index fell by more than 2%. Among them, Sutro Biopharma dropped 12.98%, Kyverna Therapeutics fell 10.95%, GRAIL decreased 10.01%, and Pyxis Oncology declined 9.34%. Ironwood Pharma rose 4.44%, Arrowhead Pharmaceuticals increased 4.63%, Neumora Therapeutics grew 6.92%, and Q32 Bio surged 92.69%

    Wallstreetcn·
    US
    IRWD
    0.00%
    US
    STRO
    +7.82%
    US
    NMRA
    +0.22%
    Wallstreetcn·
    US
    IRWD
    0.00%
    US
    STRO
    +7.82%
    US
    NMRA
    +0.22%

    Ironwood Pharma’s LINZESS® Price Set by HHS

    Ironwood Pharmaceuticals announced that the U.S. Department of Health and Human Services has set the 'Maximum Fair Price' for LINZESS® (linaclotide) at $136 for a 30-day supply, effective January 1, 2027, under the Inflation Reduction Act of 2022. This aligns with the company's expectations. The latest analyst rating for Ironwood Pharma (IRWD) stock is a Hold with a $3.00 price target. Despite bullish technical momentum, financial challenges and overbought indicators suggest caution for investors.

    Tip Ranks·
    US
    IRWD
    0.00%
    Tip Ranks·
    US
    IRWD
    0.00%

    BUZZ-Ironwood rises after US sets Medicare price for constipation drug

    Shares of drugmaker Ironwood Pharmaceuticals’shares rise 1.3% to $3.17 premarketCo says U.S. Department of Health and Human Services has set the new Medicare price for co’s Linzess at $136 for a 30-day supplyCo’s Linzess treats chronic constipation and irritable bowel syndrome with constipation - IRWDNew price will apply from Jan. 1, 2027 under Inflation Reduction Act, co saysCo says revised price aligns with its expectationsUp to last close, stock down ~30% YTD

    Reuters·
    US
    IRWD
    0.00%
    Reuters·
    US
    IRWD
    0.00%

    17:31 ET Short Bowel Syndrome Market to Register Stunning Growth at a CAGR of 5% During the Forecast Period (2025-2034) Owing to the Launch of Novel GLP-2 Analogues | DelveInsight

    DelveInsight projects the short bowel syndrome market to grow at a 5% CAGR from 2025-2034, driven by novel GLP-2 analogues like apraglutide and glepaglutide. The market size in the US was USD 2.1 billion in 2024, with rising SBS prevalence and new therapies enhancing patient outcomes. Companies like Ironwood Pharmaceuticals and Zealand Pharma are developing promising treatments, with glepaglutide expected to launch first in Europe.

    prnewswire·
    US
    IRWD
    0.00%
    prnewswire·
    US
    IRWD
    0.00%

    VP Gaskins Files To Sell 6,324 Of Ironwood Pharmaceuticals Inc [IRWD]

    VP Tammi L. Gaskins of Ironwood Pharmaceuticals Inc filed a Form 144 with the SEC to sell 6,324 restricted shares on November 14, 2025. The sale is planned for November 17, 2025, through E-TRADE Securities LLC. Form 144 is required for selling restricted stock, allowing sales within 90 days of filing.

    Reuters·
    US
    IRWD
    0.00%
    Reuters·
    US
    IRWD
    0.00%
    © 2025 Longbridge｜Disclaimer